What is the appropriate assessment and management plan for an 89‑year‑old woman with chronic bilateral lower‑extremity lymphedema, heart failure with mid‑range ejection fraction, atrial fibrillation (Watchman device), tachy‑brady syndrome with pacemaker, type 2 diabetes, chronic kidney disease, presenting with progressive leg aching and edema after stopping compression therapy, polyuria, recent urinary tract infection treated with antibiotics, mild orthopnea, occasional orthostatic light‑headedness, right ankle sprain, mild leukocytosis, hyperkalemia, metabolic acidosis with elevated anion gap, baseline creatinine, elevated B‑type natriuretic peptide, rising troponin, and urinalysis showing glucosuria, mild proteinuria and hematuria?

Assessment and Management of an 89-Year-Old Woman with Decompensated Heart Failure and Multiple Comorbidities

This patient is experiencing acute decompensated heart failure (ADHF) with evidence of pulmonary edema, rising troponin suggesting myocardial injury, and metabolic derangements—she requires immediate hospital admission with aggressive diuretic therapy, careful monitoring of renal function and electrolytes, and urgent echocardiography to assess current cardiac function and guide management.

Primary Clinical Problem: Acute Decompensated Heart Failure

The constellation of findings—mild pulmonary edema on chest X-ray, elevated BNP (463), orthopnea, bilateral lower extremity edema worsening after stopping compression therapy, and polyuria from dapagliflozin—clearly indicates ADHF superimposed on chronic heart failure with mid-range ejection fraction 1.

Critical Red Flags Requiring Immediate Action:

• Rising troponin (24→43): This suggests acute myocardial injury, potentially from demand ischemia in the setting of decompensation or an acute coronary syndrome. While the ECG shows no STEMI, this warrants serial troponins and cardiology consultation 1.

• Metabolic acidosis with elevated anion gap (17): Combined with hyperkalemia (5.2) and creatinine 1.3, this suggests either type B lactic acidosis from poor perfusion or euglycemic diabetic ketoacidosis (eDKA) from dapagliflozin—the 4+ urine glucose supports ongoing SGLT2 inhibitor effect 2.

• Hyperkalemia (5.2): In the context of CKD, valsartan use, and metabolic acidosis, this requires immediate management and may necessitate temporary discontinuation of RAS inhibition 2.

Immediate Management Algorithm

Step 1: Address Life-Threatening Issues

Discontinue dapagliflozin immediately. The combination of polyuria, metabolic acidosis with elevated anion gap, and 4+ urine glucose raises concern for eDKA—a known complication of SGLT2 inhibitors that can occur even with normal blood glucose 2. The polyuria is exacerbating volume depletion despite total body fluid overload.

Manage hyperkalemia: With potassium at 5.2 and metabolic acidosis, initiate treatment with:

• Calcium gluconate if ECG changes present
• Insulin/dextrose
• Sodium bicarbonate (addresses both acidosis and hyperkalemia)
• Consider patiromer or sodium zirconium cyclosilicate for sustained control 2

Hold valsartan temporarily until potassium normalizes and acidosis resolves, then restart at lower dose 2.

Step 2: Restore Euvolemia with Aggressive Diuresis

The patient requires intravenous loop diuretics despite her previous refusal. Her current regimen is inadequate—she stopped compression therapy (the primary treatment for lymphedema) and is on only 5mg dapagliflozin, which she must now discontinue 1, 3.

Initiate IV furosemide:

• Start with 40-80mg IV bolus (higher dose given chronic diuretic resistance from lymphedema and prior non-adherence)
• Monitor urine output closely; if inadequate response within 2 hours, double the dose
• Target net negative fluid balance of 1-2 liters daily until euvolemia achieved 3

If diuretic resistance develops:

• Add metolazone 2.5-5mg daily (thiazide-type diuretic with synergistic effect) 1, 3
• Consider continuous IV furosemide infusion
• Monitor electrolytes and creatinine every 12-24 hours during aggressive diuresis 3

Critical point: Do not discharge until euvolemia is achieved and stable oral diuretic regimen established. Patients discharged before reaching euvolemia have high readmission rates 3.

Step 3: Cardiac Workup for Rising Troponin

Obtain urgent echocardiography to:

• Assess current ejection fraction (baseline was mid-range)
• Evaluate for new wall motion abnormalities suggesting ischemia
• Assess valvular function and filling pressures
• Rule out complications (e.g., pericardial effusion) 1

Serial troponins every 6-8 hours to determine if rising, plateauing, or falling. If continuing to rise, consider coronary angiography despite DNR/DNI status, as revascularization could improve quality of life 1.

Step 4: Address the Lymphedema Crisis

The worsening leg symptoms are primarily from lymphedema exacerbation after stopping compression therapy, NOT from heart failure alone 4, 5. The chronic bilateral lymphedema creates a vicious cycle with heart failure—lymphatic dysfunction causes fluid overload and inflammation, which worsens cardiac function 4.

Once euvolemia achieved:

• Restart compression therapy with proper fitting and patient education about gradual application
• Consider wraps instead of stockings if she found stockings too constrictive
• Physical therapy consultation for manual lymphatic drainage
• Elevate legs when sitting/lying
• Skin care to prevent cellulitis (given blisters present) 6, 7

Address the right ankle injury: The pain from PT "twisting" her ankle needs evaluation—obtain X-ray to rule out fracture, as this could be limiting mobility and worsening venous/lymphatic stasis.

Medication Reconciliation and Optimization

Current Regimen Issues:

1. Dapagliflozin 5mg daily: STOP immediately due to eDKA concern and polyuria contributing to dehydration 2

2. Carvedilol 3.125mg BID: Continue—beta-blockers improve mortality in HFrEF and HFmrEF, though dose is suboptimal 1. Once stabilized, uptitrate gradually to target dose (25mg BID) as tolerated by blood pressure and heart rate.

3. Valsartan 40mg daily: Hold temporarily for hyperkalemia, restart at 40mg once K+ <5.0 and creatinine stable 2. This dose is suboptimal; target is 160mg BID, but advance cautiously given age and renal function.

4. Letrozole 2.5mg: Continue for breast cancer history.

Critical Missing Medications:

Loop diuretic is essential—her refusal of furosemide due to urination frequency must be addressed through patient education. Explain that:

• Uncontrolled fluid overload will kill her faster than the inconvenience of urination
• Once euvolemia achieved, diuretic dose can be reduced to maintenance level
• Timing doses in morning/early afternoon minimizes nighttime urination 1

Consider adding spironolactone 12.5-25mg daily once hyperkalemia resolves and patient is euvolemic. Aldosterone antagonists reduce mortality in advanced heart failure (NYHA III-IV) 1. Monitor potassium closely given CKD and RAS inhibition.

Addressing the Urinary Tract Infection

The "markedly increased urinary frequency" with clear urine and no dysuria is likely from dapagliflozin-induced osmotic diuresis, NOT recurrent UTI. The urinalysis shows:

• 1+ protein, 1+ blood (consistent with CKD)
• Negative nitrites (argues against bacterial infection)
• 4+ glucose (from SGLT2 inhibitor)
• No RBCs despite 1+ blood (suggests hemoglobinuria or myoglobinuria)

Recommendation: Send urine culture. If negative, discontinue antibiotics started in ED. If positive, complete appropriate antibiotic course but recognize that polyuria will resolve with dapagliflozin discontinuation, not antibiotics.

Monitoring Plan During Hospitalization

Daily assessments:

• Weight (same scale, same time, after voiding)
• Strict intake/output
• Physical exam focusing on JVP, lung crackles, peripheral edema
• Orthostatic vital signs (given lightheadedness)

Laboratory monitoring:

• BMP every 12-24 hours during aggressive diuresis
• Troponin every 6-8 hours until trending down
• BNP after achieving euvolemia (should decrease significantly)
• Venous blood gas if acidosis persists

Acceptable changes during diuresis:

• Creatinine increase up to 30% from baseline is acceptable if patient becoming euvolemic 2
• BUN may rise disproportionately (prerenal pattern)
• These changes should NOT prompt diuretic reduction if patient remains volume overloaded 3

Renal Function Considerations

Her creatinine of 1.3 with CKD requires careful attention. The metabolic acidosis (bicarb 19.2) and hyperkalemia suggest CKD stage 3b-4 (eGFR likely 30-45 ml/min/1.73m²) 8, 2.

Key principles:

• Hemodynamic changes from heart failure (decreased forward flow, venous congestion) are potentially reversible causes of worsening renal function 8
• Aggressive diuresis may transiently worsen creatinine but improves long-term renal perfusion by reducing venous congestion 8
• Continue valsartan even if eGFR falls below 30, unless creatinine rises >30% or hyperkalemia uncontrollable 2

Goals of Care Discussion

The patient's DNR/DNI status is appropriate and should be honored. However, clarify:

• Does she want hospitalization for acute illnesses like this?
• Would she want dialysis if kidneys fail?
• What are her quality-of-life priorities?

Given her age (89), multiple comorbidities, and functional decline, consider palliative care consultation to ensure symptom management aligns with her goals 3.

Discharge Planning (Once Stabilized)

Do not discharge until:

1. Euvolemia achieved (no orthopnea, clear lungs, minimal leg edema)
2. Stable oral diuretic regimen established
3. Patient/family educated on daily weights and when to call
4. Compression therapy restarted and tolerated
5. Follow-up arranged within 7 days

Discharge medications should include:

• Furosemide 40-80mg daily (adjust based on response)
• Carvedilol 3.125mg BID (uptitrate as outpatient)
• Valsartan 40mg daily (restart once K+ normal)
• Spironolactone 12.5-25mg daily (if K+ permits)
• NOT dapagliflozin (contraindicated given eDKA risk and her inability to tolerate polyuria)

Patient education priorities:

• Daily weights at same time; call if gain >2-3 lbs in 1 day or 5 lbs in 1 week
• Sodium restriction to <2g daily 1
• Fluid restriction to 1.5-2L daily if hyponatremia develops
• Compression therapy is non-negotiable for lymphedema control
• Medication adherence is critical—set up pill organizer and caregiver supervision

Common Pitfalls to Avoid

1. Discharging before euvolemia: This guarantees readmission within days 3

2. Stopping RAS inhibition for mild creatinine elevation: Up to 30% increase is acceptable and expected 2

3. Undertreating volume overload due to fear of worsening renal function: Venous congestion damages kidneys more than aggressive diuresis 8

4. Ignoring the lymphedema: This is a cardiovascular disorder that perpetuates heart failure through fluid overload and inflammation 4

5. Restarting dapagliflozin: While SGLT2 inhibitors have mortality benefit in heart failure, this patient cannot tolerate the polyuria and is at risk for eDKA 2

6. Accepting medication non-adherence: Her admission that she "sometimes takes one dose instead of two" explains the decompensation. Address this directly with simplified regimen and caregiver involvement.